Methylcellulose

證據等級: L5

預測適應症: 10 個

Methylcellulose: From Bulk-Forming Laxative/Excipient Use to Osteoarthritis

One-Sentence Summary

Methylcellulose is a non-absorbed cellulose derivative traditionally used as a bulk-forming laxative and as a pharmaceutical/food excipient; it is not currently marketed in South Africa and has no on-file original indication. The TxGNN model predicts a possible new use in Osteoarthritis, but this is currently supported only by 2 clinical trials of uncertain relevance and 19 publications, nearly all describing methylcellulose as a hydrogel/delivery vehicle rather than an active therapeutic agent.

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (no SAHPRA licenses on file; drug not marketed)
Predicted New Indication	Osteoarthritis
TxGNN Prediction Score	95.21%
Evidence Level	L4
South Africa Market Status	Not Marketed
Number of SAHPRA Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for methylcellulose is not available. Based on known information, methylcellulose is a non-absorbed, bulk-forming polysaccharide used mainly as a laxative (increasing stool water content and bowel motility) and, separately, as a pharmaceutical excipient — it has no established systemic pharmacological activity and no known direct mechanism affecting joints or cartilage.

Nearly all of the osteoarthritis-related literature identified treats methylcellulose not as a therapeutic agent in its own right, but as a hydrogel or delivery-vehicle excipient that carries other active molecules — for example TIMP3 protein, curcumin, or celecoxib — to the joint or skin surface. In these studies, the therapeutic effect is attributed to the co-formulated active ingredient, not to methylcellulose itself.

Given this, the high TxGNN score most plausibly reflects frequent textual co-occurrence of “methylcellulose” with “osteoarthritis” in biomaterials and drug-delivery literature, rather than a genuine, independent pharmacological signal. This distinction is the central caveat for interpreting this candidate.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01478997	Phase 1/2	Completed	76	Evaluated “Flexsure” for safety, tolerability and efficacy in moderate knee osteoarthritis; the study title does not identify methylcellulose as the active investigational agent, and it may only be a formulation component (Relevance grade C).
NCT04207021	N/A	Unknown	134	Evaluated a curcumin-based food supplement for OA pain/inflammation; methylcellulose is not the study drug (Relevance grade C).

Neither trial directly tests methylcellulose as an active treatment for osteoarthritis.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
40354857	2025	Preclinical/Biomaterial	Int J Biol Macromol	Nanozyme-loaded F127/methylcellulose transdermal hydrogel for OA immunomodulation; methylcellulose used as hydrogel matrix.
30767746	2020	Formulation study	Curr Rheumatol Rev	Herbal curcumin/arnica topical patch for OA; methylcellulose relevance is formulation-level only.
37321710	2023	Preclinical/Biomaterial	Carbohydrate Polymers	Sulfated carboxymethylcellulose used to deliver TIMP3 protein, attenuating OA via NF-κB/JNK inhibition; active agent is TIMP3, not methylcellulose.
41054792	2025	Preclinical/Biomaterial	Artif Cells Nanomed Biotechnol	Methylcellulose-carboxymethyl chitosan hydrogel delivering mesenchymal stromal cell spheroids for cartilage regeneration.
25468298	2015	Preclinical/Tissue engineering	J Biomech	Polymer coatings (including carboxymethylcellulose) applied to resurface damaged cartilage; structure-modifying approach, not a drug effect.
26752990	2015	In vitro/formulation	Res Pharm Sci	Iontophoretic transdermal delivery of celecoxib using a cellulose-based gel; active agent is celecoxib.
35588980	2022	Preclinical/Biomaterial	Int J Biol Macromol	Sulfated carboxymethylcellulose scaffold delivering TIMP3 to alleviate OA; active agent is TIMP3.
32027902	2020	Preclinical/Biomaterial	Int J Biol Macromol	Methylcellulose-based hydrogel encapsulating meloxicam-loaded nanoparticles; active agent is meloxicam.
38815684	2024	Preclinical/Device concept	Acta Biomater	Small finger-joint implant material study for hand OA; methylcellulose not the focus.
36079990	2022	Formulation optimization	Nanomaterials (Basel)	Proanthocyanidin-loaded transferosomes formulated in a 4% methylcellulose gel for OA; active agent is proanthocyanidin.

No randomized controlled trial or systematic review evaluating methylcellulose itself as an OA treatment was found; all listed studies use it as an excipient or delivery vehicle for another active compound.

South Africa Market Information

Methylcellulose has no SAHPRA-registered products on file and is currently not marketed in South Africa (0 registrations). No product, dosage form, or approved indication data is available to tabulate.

Safety Considerations

Please refer to the SAHPRA-approved Professional Information (PI) for safety information. Report adverse drug reactions to SAHPRA.

Conclusion and Next Steps

Decision: Hold

Rationale: The evidence base for methylcellulose in osteoarthritis is mechanistically weak: methylcellulose has no known systemic pharmacological activity, and virtually all supporting literature describes it as an inert hydrogel/delivery excipient carrying other active compounds (TIMP3, curcumin, celecoxib, meloxicam) rather than acting as a therapeutic agent itself. No dedicated RCT tests methylcellulose as an active OA treatment, and the drug is not currently marketed in South Africa.

To proceed, the following is needed:

Confirmed mechanism of action (MOA) data for methylcellulose
A dedicated clinical trial or pharmacological study testing methylcellulose (not as an excipient) against a validated OA endpoint
SAHPRA-approved Professional Information (PI) for warnings, contraindications, and drug interactions
Reassessment of whether the TxGNN score reflects a genuine pharmacological signal versus literature co-occurrence bias, before any advancement beyond S0/S1
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.